Open AccessSequential Protocols using Basiliximab versus Anti-Thymocyte Globulins in Renal-Transplant Patients Receiving Mycophenolate Mofetil and Steroids
Author(s) -
Georges Mourad,
Lionel Rostaing,
Christophe Legendre,
V. Garrigue,
Éric Thervet,
Dominique Durand
Publication year - 2004
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/01.tp.0000129812.68794.cc
Subject(s) - basiliximab , medicine , anti thymocyte globulin , gastroenterology , mycophenolic acid , immunosuppression , transplantation , creatinine , immunology , urology , kidney transplantation
Sequential anti-thymocyte globulins (ATG)/cyclosporine immunosuppression has two main advantages: delayed introduction of the nephrotoxic drug cyclosporine and prevention of acute rejection. Basiliximab, a recently developed chimeric monoclonal antibody that selectively depletes the minor subpopulation of activated T lymphocytes, has been shown to reduce the incidence of acute rejection when used with cyclosporine introduced on day 1.